Zoetis Inc. $ZTS Shares Sold by Capital Analysts LLC

Key Points

• Capital Analysts LLC cut its Zoetis position by 99% in the second quarter, selling 81,991 shares and retaining 787 shares worth approximately $56,000. Institutional investors and hedge funds collectively own 92.8% of the company.
• Zoetis reported quarterly EPS of $1.87, slightly above the $1.85 analyst consensus, while revenue of $2.47 billion fell short of estimates and declined 0.2% year over year.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $101.08; several firms recently lowered their targets to roughly $80–$94.

Capital Analysts LLC trimmed its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 99.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 787 shares of the company's stock after selling 81,991 shares during the period. Capital Analysts LLC's holdings in Zoetis were worth $56,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Prosperity Bancshares Inc purchased a new stake in Zoetis in the 4th quarter valued at approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis in the 1st quarter valued at approximately $28,000. Elyxium Wealth LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $32,000. Root Financial Partners LLC boosted its stake in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after buying an additional 103 shares in the last quarter. Finally, Wellington Grp LLC boosted its stake in shares of Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company's stock valued at $32,000 after buying an additional 267 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

NYSE ZTS opened at $73.05 on Monday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a fifty-two week low of $71.00 and a fifty-two week high of $150.05. The business has a fifty day moving average of $75.56 and a 200-day moving average of $91.73. The stock has a market cap of $30.19 billion, a price-to-earnings ratio of 12.03, a price-to-earnings-growth ratio of 1.70 and a beta of 0.73.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts' consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business's revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter last year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ZTS shares. TD Cowen decreased their target price on shares of Zoetis from $104.00 to $94.00 and set a "buy" rating on the stock in a research report on Tuesday, August 25th. UBS Group reduced their price objective on shares of Zoetis from $85.00 to $80.00 and set a "neutral" rating for the company in a research note on Friday, August 7th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $85.00 to $80.00 and set a "hold" rating on the stock in a report on Thursday, August 20th. Weiss Ratings restated a "sell (d)" rating on shares of Zoetis in a research report on Wednesday. Finally, Piper Sandler dropped their target price on shares of Zoetis from $90.00 to $80.00 and set a "neutral" rating for the company in a report on Monday, August 10th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Zoetis presently has a consensus rating of "Hold" and an average price target of $101.08.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.